Population pharmacokinetics and exposure–response of selumetinib and its N‐desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas-Reference-Cited by-同舟云学术

Population pharmacokinetics and exposure–response of selumetinib and its N‐desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas

Published:2021-04-26 Issue:2 Volume:88 Page:189-202
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Schalkwijk Stein^ORCID,Zhou Li,Cohen‐Rabbie Sarit,Jain Lokesh,Freshwater Tomoko,So Karen,He Zhongqing,Gioni Ioanna,Tomkinson Helen,Vishwanathan Karthick,Zhou Diansong

Funder

AstraZeneca

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00280-021-04274-6.pdf

Reference31 articles.

1. Ferner RE (2007) Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol 6(4):340–351. https://doi.org/10.1016/s1474-4422(07)70075-3

2. Nguyen R, Kluwe L, Fuensterer C, Kentsch M, Friedrich RE, Mautner VF (2011) Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and associated clinical deficits. J Pediatr 159(4):652-655.e652. https://doi.org/10.1016/j.jpeds.2011.04.008

3. Viskochil D, White R, Cawthon R (1993) The neurofibromatosis type 1 gene. Annu Rev Neurosci 16:183–205. https://doi.org/10.1146/annurev.ne.16.030193.001151